Company: SUPN
Filing Date: 2025-02-25
Form Type: 10-K
Source: 0001356576-25-000017
Chunk: 214

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-02-25
Form: 10-K
Item: Item 8
Chunk 214
---
 adoption of ASU 2020-06— — (56,212)— 40,612 (15,600)Balance, January 1, 202253,256,094 53 378,125 1,539 420,534 800,251 Share-based compensation expense related to employee stock purchase plan and share-based awards— — 17,568 — — 17,568 Issuance of common stock related to employee stock purchase plan and share-based awards997,702 1 12,422 — — 12,423 Net earnings— — — — 60,711 60,711 Unrealized loss on marketable securities, net of tax— — — (4,749)— (4,749)Balance, December 31, 202254,253,796 54 408,115 (3,210)481,245 886,204 Share-based compensation expense related to employee stock purchase plan and share-based awards— — 26,759 — — 26,759 Issuance of common stock related to employee stock purchase plan and share-based awards469,560 1 4,619 — — 4,620 Net earnings— — — — 1,316 1,316 Unrealized gain on marketable securities, net of tax— — — 2,617 — 2,617 Balance, December 31, 202354,723,356 55 439,493 (593)482,561 921,516 Share-based compensation expense related to employee stock purchase plan and share-based awards— — 27,755 — — 27,755 Issuance of common stock related to employee stock purchase plan and share-based awards, net of taxes withheld1,019,739 1 12,192 — — 12,193 Net earnings— — — — 73,865 73,865 Unrealized gain on marketable securities, net of tax— — — 404 — 404 Balance, December 31, 202455,743,095 $56 $479,440 $(189)$556,426 $1,035,733 

See accompanying notes.

95

Supernus Pharmaceuticals, Inc.

Consolidated